GigaGen CEO David Johnson to Present Data from Surge Platform at American Association for Cancer Research Annual Meeting 2018

,

GigaGen Inc., a biopharmaceutical company developing novel antibody therapies, today announced that David Johnson, Ph.D., chief executive officer, will present data from the company’s proprietary Surge platform at the American Association for Cancer Research (AACR) Annual Meeting 2018. The conference will take place April 14-18, 2018, at the McCormick Place in Chicago.

Read the full press release.

Nature Biotechnology: GigaGen Recognized as One of the Top Biotech Startups Funded in 2017

,

Our annual survey highlights how immune-oncology and screens based on the application of cutting-edge omics technologies are providing a launchpad for a succession of startups interrogating biology across biomedicine.

Read the full story.

GigaGen Presents Methods for Rapid Immuno-Oncology Antibody Discovery at 2018 Keystone Symposia on Antibodies as Drugs

,

GigaGen Inc., a biopharmaceutical company developing novel antibody therapies, presented preclinical research on its industry-leading Surge™ technology at the 2018 Keystone Symposia on Antibodies as Drugs: Translating Molecules into Treatments. In its research, GigaGen used Surge, a high-throughput single cell droplet microfluidic technology, to rapidly discover high-affinity, fully human antibody drug candidates against 17 immuno-oncology targets — far exceeding what is possible through conventional hybridoma screening.

Read the full press release.

GigaGen Announces Appointment of Jan Fredrik Simons, Ph.D., as Senior Director, Technology

,

GigaGen Inc., a biopharmaceutical company developing novel antibody therapies, today announced that Jan Fredrik Simons, Ph.D., has joined the company as Senior Director, Technology.

Read the full press release.

Biotech Showcase 2018

,

David S. Johnson, PhD, MBA, Chief Executive Officer and Co-Founder, GigaGen, speaks to SCRIP about the company’s pipeline and business strategy.

Watch the video.

GigaGen to Present Novel Antibody Development and T Cell Discovery Methods at 2018 Keystone Symposia Conferences

,

GigaGen Inc., a biopharmaceutical company developing novel antibody therapies, will be presenting the findings of its research on novel approaches to antibody development and T cell discovery for diseases of immune dysregulation at two upcoming Keystone Symposia conferences. The first conference, “Emerging Cellular Therapies: T Cells and Beyond,” will take place Feb. 11-15 in Keystone, Colo., and the second, “Antibodies as Drugs: Translating Molecules into Treatments,” will be held Feb. 25-March 1 in Whistler, British Columbia.

Read the full press release.

Life Science Leader: GigaGen CEO Dave Johnson discusses what Drug Developers can learn from Silicon Valley

,

I think Silicon Valley’s most valuable asset is a ruthless focus on experimenting with product- market fit. Silicon Valley software companies have the mentality of pushing out products, getting market feedback, and then going back to the drawing board if the market responds poorly. Imperfect products are a learning experience — an experiment — rather than a reason to close shop or fire people.

Read the full story.

Natively Paired Antibodies Are Better: Study by GigaGen in Collaboration with Global Biopharmaceutical Company Describes Novel Approach to Identifying Antibodies with High Therapeutic Potential

,

GigaGen Inc., a biopharmaceutical company developing a pipeline of novel antibody therapies, has published a study in collaboration with authors from a leading antibody drug developer that sheds new light on methods for increasing the success of antibody discovery in mice. The study, “A natively paired antibody library yields drug leads with higher sensitivity and specificity than a randomly paired antibody library,” is available online and will appear in the upcoming issue of the peer-reviewed scientific journal mAbs.

Read the full press release.

GigaGen Announces New Office Space in South San Francisco

,

GigaGen Inc., a biopharmaceutical company developing novel antibody therapies, today announced that in order to expand operations it has moved to larger office facilities located at One Tower Place, Suite 750, in South San Francisco, CA. GigaGen now occupies the 7th floor of the building, with the roughly 15,000 square foot area affording ample state-of-the-art laboratory space to accommodate the company’s expanding research and development activities and hiring plans for 2018 and beyond. GigaGen completed relocation to One Tower Place in late December 2017.

Read the full press release.

GigaGen Receives NIH Grant to Develop Production Technology for Recombinant Intravenous Immunoglobulin

,

GigaGen Inc., a biopharmaceutical company developing novel antibody therapies, has been awarded a $3 million grant from the National Institutes of Health (NIH) to advance its next-generation plasma therapy for patients with immune deficiencies. GigaGen will use the funds to develop a natural repertoire antibody protein expression system, laying the foundation for a recombinant immunoglobulin (rIVIG) therapy for patients with primary immunodeficiency diseases (PI) that overcomes many of the limitations of current plasma-based IVIG options.

Read the full press release.